The present study consists of a retrospective multicentric collection of all consecutive patients with PMBCL diagnosed over the time period considered (13 years, from 2007 to 2019 inclusive).
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Rate of primary/early refractory disease
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
Overall response rate (ORR)
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
Complete response rate (CRR)
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
Frequency of administration of mediastinal radiation therapy
Timeframe: four months after completion of chemotherapy
Progression Free Survival (PFS)
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)
Overall Survival (OS)
Timeframe: The endpoint will be evaluated from the beginning to the end of the study (up to 24 months)